IL164257A0 - 3-Heteroaryl-3,5-dihydro-4-oxo-4h-pyridazinoÄ4,5-bÜindole-1-acetamide derivatives, preparation and use thereof in medicaments - Google Patents

3-Heteroaryl-3,5-dihydro-4-oxo-4h-pyridazinoÄ4,5-bÜindole-1-acetamide derivatives, preparation and use thereof in medicaments

Info

Publication number
IL164257A0
IL164257A0 IL16425703A IL16425703A IL164257A0 IL 164257 A0 IL164257 A0 IL 164257A0 IL 16425703 A IL16425703 A IL 16425703A IL 16425703 A IL16425703 A IL 16425703A IL 164257 A0 IL164257 A0 IL 164257A0
Authority
IL
Israel
Prior art keywords
sub
büindole
medicaments
dihydro
heteroaryl
Prior art date
Application number
IL16425703A
Other languages
English (en)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of IL164257A0 publication Critical patent/IL164257A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
IL16425703A 2002-04-03 2003-04-02 3-Heteroaryl-3,5-dihydro-4-oxo-4h-pyridazinoÄ4,5-bÜindole-1-acetamide derivatives, preparation and use thereof in medicaments IL164257A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0204158A FR2838124B1 (fr) 2002-04-03 2002-04-03 Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-acetamide, leur preparation et leur application en therapeutique
PCT/FR2003/001027 WO2003082874A2 (fr) 2002-04-03 2003-04-02 DERIVES DE 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO[4,5-b]INDOLE-1-ACETAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Publications (1)

Publication Number Publication Date
IL164257A0 true IL164257A0 (en) 2005-12-18

Family

ID=28052083

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16425703A IL164257A0 (en) 2002-04-03 2003-04-02 3-Heteroaryl-3,5-dihydro-4-oxo-4h-pyridazinoÄ4,5-bÜindole-1-acetamide derivatives, preparation and use thereof in medicaments
IL164257A IL164257A (en) 2002-04-03 2004-09-23 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1- acetamide derivatives, their preparation and use thereof in medicaments

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL164257A IL164257A (en) 2002-04-03 2004-09-23 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1- acetamide derivatives, their preparation and use thereof in medicaments

Country Status (29)

Country Link
US (4) US7235554B2 (ko)
EP (1) EP1492792B1 (ko)
JP (2) JP4575670B2 (ko)
KR (1) KR100975999B1 (ko)
CN (2) CN100543016C (ko)
AT (1) ATE321763T1 (ko)
AU (1) AU2003240930B2 (ko)
BR (1) BR0309018A (ko)
CA (1) CA2481460C (ko)
CY (1) CY1104998T1 (ko)
DE (1) DE60304327T2 (ko)
DK (1) DK1492792T3 (ko)
EA (1) EA007219B1 (ko)
ES (1) ES2261940T3 (ko)
FR (1) FR2838124B1 (ko)
HK (2) HK1074632A1 (ko)
HR (1) HRP20040911B1 (ko)
IL (2) IL164257A0 (ko)
IS (1) IS2483B (ko)
ME (2) MEP23708A (ko)
MX (1) MXPA04009635A (ko)
NO (1) NO329426B1 (ko)
NZ (1) NZ535741A (ko)
PL (1) PL372617A1 (ko)
PT (1) PT1492792E (ko)
RS (1) RS51244B (ko)
UA (1) UA77273C2 (ko)
WO (1) WO2003082874A2 (ko)
ZA (1) ZA200407945B (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1786905B1 (en) * 2004-08-18 2011-08-03 Lorus Therapeutics Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
US7687501B2 (en) * 2005-08-19 2010-03-30 Schering Corporation Pyridothienopyridazinone derivatives as mGluR1 antagonists
CN102300851A (zh) * 2009-01-30 2011-12-28 阿斯利康(瑞典)有限公司 制备含羧基的吡唑酰氨基化合物597的新方法
CN105330665B (zh) * 2015-11-04 2017-10-03 衡阳师范学院 一种抑制激肽释放酶klk7的化合物、制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754262B1 (fr) * 1996-10-08 1998-10-30 Synthelabo Derives de 1h-pyrido[3,4-b]indole-4-carboxamide, leur preparation et leur application en therapeutique
FR2766823B1 (fr) * 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
FR2788776B1 (fr) * 1999-01-26 2001-02-23 Synthelabo Derives de 4-oxo-3, 5-dihydro-4h-pyridazino [4,5-b] indole-1 -carboxamide, leur preparation et leur application en therapeutique
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
FR2811990A1 (fr) * 2000-07-24 2002-01-25 Sanofi Synthelabo DERIVES DE 1-(4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b]INDOLE-1 -CARBONYL)PIPERAZINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2811897A1 (fr) * 2000-07-24 2002-01-25 Sanofi Synthelabo UTILISATION DE DERIVES DE PYRIDAZINO[4,5-b]INDOLE-1- ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AU TRAITEMENT DES DYSFONCTIONNEMENTS DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES
FR2833953B1 (fr) * 2001-12-21 2004-12-03 Sanofi Synthelabo DERIVES DE 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO [4,5-b]INDOLE-1-CARBOXAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Also Published As

Publication number Publication date
EA200401146A1 (ru) 2005-06-30
AU2003240930B2 (en) 2009-07-30
EP1492792A2 (fr) 2005-01-05
US7235554B2 (en) 2007-06-26
ME00081B (me) 2010-10-10
CA2481460A1 (en) 2003-10-09
US20080255129A1 (en) 2008-10-16
IS7478A (is) 2004-09-30
ZA200407945B (en) 2005-11-30
WO2003082874A2 (fr) 2003-10-09
NO329426B1 (no) 2010-10-18
US20050124615A1 (en) 2005-06-09
CN1970538A (zh) 2007-05-30
HK1074632A1 (en) 2005-11-18
NO20044153L (no) 2004-12-27
NZ535741A (en) 2007-03-30
US7323467B2 (en) 2008-01-29
FR2838124A1 (fr) 2003-10-10
IL164257A (en) 2009-11-18
MXPA04009635A (es) 2005-07-13
IS2483B (is) 2008-12-15
CY1104998T1 (el) 2009-11-04
EP1492792B1 (fr) 2006-03-29
CN100406459C (zh) 2008-07-30
DE60304327T2 (de) 2006-12-28
KR100975999B1 (ko) 2010-08-17
JP2010248221A (ja) 2010-11-04
ATE321763T1 (de) 2006-04-15
WO2003082874A3 (fr) 2004-04-01
AU2003240930A1 (en) 2003-10-13
JP4575670B2 (ja) 2010-11-04
JP5277208B2 (ja) 2013-08-28
DE60304327D1 (de) 2006-05-18
MEP23708A (en) 2010-06-10
DK1492792T3 (da) 2006-08-14
HRP20040911B1 (en) 2012-11-30
FR2838124B1 (fr) 2004-05-28
PT1492792E (pt) 2006-08-31
RS51244B (sr) 2010-12-31
US20070219202A1 (en) 2007-09-20
UA77273C2 (en) 2006-11-15
KR20040094904A (ko) 2004-11-10
CN1656099A (zh) 2005-08-17
EA007219B1 (ru) 2006-08-25
JP2005527566A (ja) 2005-09-15
CN100543016C (zh) 2009-09-23
PL372617A1 (en) 2005-07-25
ES2261940T3 (es) 2006-11-16
HK1102371A1 (en) 2007-11-16
US7405306B2 (en) 2008-07-29
US20080076775A1 (en) 2008-03-27
HRP20040911A2 (en) 2004-12-31
RS86904A (en) 2006-12-15
BR0309018A (pt) 2005-02-01
CA2481460C (en) 2011-02-15

Similar Documents

Publication Publication Date Title
HRP20020712B1 (hr) Farmaceutske strukture koje sadrže derivate azetidina, novi derivati azetidina i njihovo pripremanje
HUP0303398A2 (hu) 1,2-Dihidropiridin-származékok, eljárás előállításukra és alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények
TR200102490T2 (tr) Fenil ve piridinil türevleri
TW200607808A (en) Pyrido-pyrimidine derivatives, preparation thereof and application thereof
ATE319704T1 (de) Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
HK1074632A1 (en) 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments
AU6841890A (en) Antipicornaviral pyridazinamines
AU6158486A (en) Dihydro pyridine derivatives
YU49902A (sh) Supstituisani derivati piperazina kao mtp inhibitori
CY1106029T1 (el) Παραγωγα 3-ετepοαρυλιο-3,5-διυδρο-4-οξο-4η-πυριδαζινο[4,5-β]ινδολη-1-καρβοξαμιδο, η παρασκευη τους και η εφαρμογη τους στη θepαπευτικη
UA72934C2 (uk) Феніл- і піридилтетрагідропіридини, що інгібують фактор некрозу пухлин, спосіб їх одержання та фармацевтична композиція
AU2002244985A1 (en) Thiazolidinedione derivatives and pharmaceutical composition comprising the same
WO2001034576A3 (en) Use of pyrimidinone derivatives for controlling undesired microorganisms